Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 18Terminated 13Completed 13Recruiting 9Unknown 4Withdrawn 2Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Specimen Handling 5Nivolumab 3Biopsy 3Magnetic Resonance Spectroscopy 2Docetaxel 2talazoparib 1romidepsin 1pembrolizumab 1olaparib 1imisopasem manganese 1gallium 68 PSMA-11 1durvalumab 1balstilimab 1aldesleukin 1abivertinib 1abiraterone 1abarelix 1Watchful Waiting 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Observation 1N-acetylcochinol-O-phosphate 1Mental Status and Dementia Tests 1Menogaril 1Magnetic Resonance Imaging 1Ketones 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × olaparib × Genitourinary × Clear all
NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡